Fungal infections in iatrogenically compromised hosts.
Rex
J H
JH
Department of Internal Medicine, University of Texas Medical School, Houston, USA.
Walsh
T J
TJ
Anaissie
E J
EJ
D000666:Amphotericin B / Q000627:therapeutic use; D000935:Antifungal Agents / Q000627:therapeutic use; D001228:Aspergillosis / Q000175:diagnosis* / Q000188:drug therapy / Q000517:prevention & control / Q000601:surgery; D001393:Azoles / Q000627:therapeutic use; D002177:Candidiasis / Q000175:diagnosis* / Q000188:drug therapy / Q000517:prevention & control; D002408:Catheters, Indwelling / Q000009:adverse effects; D003937:Diagnosis, Differential; D005437:Flucytosine / Q000627:therapeutic use; D005670:Fusarium; D006801:Humans; D007049:Iatrogenic Disease; D016867:Immunocompromised Host; D009181:Mycoses / Q000175:diagnosis / Q000188:drug therapy; D009894:Opportunistic Infections / Q000175:diagnosis* / Q000188:drug therapy / Q000517:prevention & control / Q000601:surgery; D013577:Syndrome; D014250:Trichosporon
D000935:Antifungal Agents; D001393:Azoles; D000666:Amphotericin B; D005437:Flucytosine